DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) have been given a consensus rating of “Moderate Buy” by the six brokerages that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $12.3333.

A number of research firms have recently commented on DMAC. Cantor Fitzgerald started coverage on DiaMedica Therapeutics in a research report on Friday, November 14th. They set an “overweight” rating for the company. Wall Street Zen cut shares of DiaMedica Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of DiaMedica Therapeutics in a research note on Wednesday, January 21st. Finally, Lake Street Capital reiterated a “buy” rating on shares of DiaMedica Therapeutics in a research report on Monday, January 5th.

DiaMedica Therapeutics Price Performance

NASDAQ DMAC opened at $7.71 on Wednesday. DiaMedica Therapeutics has a 1-year low of $3.19 and a 1-year high of $10.42. The business has a 50 day simple moving average of $8.21 and a two-hundred day simple moving average of $7.54. The stock has a market capitalization of $401.54 million, a PE ratio of -10.86 and a beta of 1.09.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in DMAC. Cooperman Leon G grew its position in DiaMedica Therapeutics by 98.2% in the third quarter. Cooperman Leon G now owns 3,269,761 shares of the company’s stock worth $22,463,000 after acquiring an additional 1,619,761 shares in the last quarter. Millennium Management LLC purchased a new stake in DiaMedica Therapeutics during the third quarter valued at approximately $8,157,000. Paragon Associates & Paragon Associates II Joint Venture lifted its stake in shares of DiaMedica Therapeutics by 34.6% in the 3rd quarter. Paragon Associates & Paragon Associates II Joint Venture now owns 875,000 shares of the company’s stock valued at $6,011,000 after purchasing an additional 225,000 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of DiaMedica Therapeutics by 7.4% in the 4th quarter. Geode Capital Management LLC now owns 764,255 shares of the company’s stock valued at $6,085,000 after purchasing an additional 52,437 shares during the last quarter. Finally, State Street Corp boosted its holdings in shares of DiaMedica Therapeutics by 31.7% in the 4th quarter. State Street Corp now owns 627,771 shares of the company’s stock worth $4,997,000 after purchasing an additional 151,188 shares during the period. Institutional investors own 10.12% of the company’s stock.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics, Inc (NASDAQ: DMAC) is a clinical‐stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company’s lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein‐kinin system. DiaMedica’s research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.

DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.